Fecal microbiota transplantation for recurrent Clostridioides difficile infection in frail and very old patients.
Clostridioides
comorbidities
fecal microbiota transplantation
frailty
very old
Journal
Journal of the American Geriatrics Society
ISSN: 1532-5415
Titre abrégé: J Am Geriatr Soc
Pays: United States
ID NLM: 7503062
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
25
05
2023
received:
21
12
2022
accepted:
19
06
2023
pubmed:
17
7
2023
medline:
17
7
2023
entrez:
17
7
2023
Statut:
ppublish
Résumé
Older age is a well-known risk factor for recurrent and severe Clostridioides difficile infection (CDI). Fecal microbiota transplantation (FMT) is widely recognized as an effective and safe therapeutic option for the treatment of recurrent CDI (rCDI). However, the efficacy and safety of FMT for rCDI in very old patients are uncertain. This study evaluated the efficacy and safety of FMT in a group of very old subjects with rCDI, and the reliability of overall comorbidity and frailty assessment for identifying patients at higher risk of worse clinical outcomes. This is a retrospective single-center study including patients ≥85 years undergoing FMT for rCDI between 2014 and 2022. Primary outcomes included efficacy of FMT, defined as cure of CDI at 8 week-follow-up, and safety evaluation. At baseline, comorbidity was measured with the Charlson Comorbidity Index (CCI). Frailty was measured with the Clinical Frailty Scale (CFS). Overall, 43 patients with a median age of 88 years underwent FMT by colonoscopy in the study period. The rate of first FMT success was 77%. Five of the 10 patients who failed the first FMT infusion were cured after repeat FMT, with an overall efficacy of 88%. In patients with successful treatment, the CFS was significantly lower compared to those who failed the FMT or underwent repeat FMT (p < 0.01 for both). Mild adverse events occurred in 11 patients (25%). One death, not related to FMT or rCDI, occurred within 7 days from the first procedure. FMT is effective and safe in very old patients. Frailty and high comorbidity do not limit use of FMT in these patients. Frailty assessment has potential to better identify patients at higher risk of worse outcomes or for repeat treatment with FMT.
Sections du résumé
BACKGROUND
BACKGROUND
Older age is a well-known risk factor for recurrent and severe Clostridioides difficile infection (CDI). Fecal microbiota transplantation (FMT) is widely recognized as an effective and safe therapeutic option for the treatment of recurrent CDI (rCDI). However, the efficacy and safety of FMT for rCDI in very old patients are uncertain. This study evaluated the efficacy and safety of FMT in a group of very old subjects with rCDI, and the reliability of overall comorbidity and frailty assessment for identifying patients at higher risk of worse clinical outcomes.
METHODS
METHODS
This is a retrospective single-center study including patients ≥85 years undergoing FMT for rCDI between 2014 and 2022. Primary outcomes included efficacy of FMT, defined as cure of CDI at 8 week-follow-up, and safety evaluation. At baseline, comorbidity was measured with the Charlson Comorbidity Index (CCI). Frailty was measured with the Clinical Frailty Scale (CFS).
RESULTS
RESULTS
Overall, 43 patients with a median age of 88 years underwent FMT by colonoscopy in the study period. The rate of first FMT success was 77%. Five of the 10 patients who failed the first FMT infusion were cured after repeat FMT, with an overall efficacy of 88%. In patients with successful treatment, the CFS was significantly lower compared to those who failed the FMT or underwent repeat FMT (p < 0.01 for both). Mild adverse events occurred in 11 patients (25%). One death, not related to FMT or rCDI, occurred within 7 days from the first procedure.
CONCLUSIONS
CONCLUSIONS
FMT is effective and safe in very old patients. Frailty and high comorbidity do not limit use of FMT in these patients. Frailty assessment has potential to better identify patients at higher risk of worse outcomes or for repeat treatment with FMT.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3530-3537Subventions
Organisme : Italian Ministry of Health-Ricerca Corrente 2023 and European Union-Next Generation EU (AGE-IT)
Informations de copyright
© 2023 The American Geriatrics Society.
Références
Czepiel J, Dróżdż M, Pituch H, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38(7):1211-1221.
Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372(16):1539-1548.
van Prehn J, Reigadas E, Vogelzang EH, et al. Guideline Committee of the European Study Group on Clostridioides difficile. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021;27:S1-S21.
Kelly CR, Fischer M, Allegretti JR, et al. ACG Clinical Guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021;116(6):1124-1147.
Burke KE, Lamont JT. Fecal transplantation for recurrent Clostridium difficile infection in older adults: a review. J Am Geriatr Soc. 2013;61(8):1394-1398.
Cammarota G, Ianiro G, Magalini S, Gasbarrini A, Gui D. Decrease in surgery for Clostridium difficile infection after starting a program to transplant fecal microbiota. Ann Intern Med. 2015;163(6):487-488.
Ianiro G, Murri R, Sciumè GD, et al. Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics: a prospective cohort study. Ann Intern Med. 2019;171(10):695-702.
Marcella C, Cui B, Kelly CR, Ianiro G, Cammarota G, Zhang F. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. Aliment Pharmacol Ther. 2021;53(1):33-42.
Tariq R, Pardi DS, Bartlett MG, Khanna S. Low cure rates in controlled trials of fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Clin Infect Dis. 2019;68(8):1351-1358.
Gupta K, Tappiti M, Nazir AM, et al. Fecal microbiota transplant in recurrent Clostridium difficile infections: a systematic review. Cureus. 2022;14(5):e24754.
Girotra M, Garg S, Anand R, Song Y, Dutta SK. Fecal microbiota transplantation for recurrent Clostridium difficile infection in the elderly: long-term outcomes and microbiota changes. Dig Dis Sci. 2016;61(10):3007-3015.
Agrawal M, Aroniadis OC, Brandt LJ, et al. The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated Clostridium difficile infection in 146 elderly individuals. J Clin Gastroenterol. 2016;50(5):403-407.
Friedman-Korn T, Livovsky DM, Maharshak N, et al. Fecal transplantation for treatment of Clostridium difficile infection in elderly and debilitated patients. Dig Dis Sci. 2018;63(1):198-203.
Nowak A, Hedenstierna M, Ursing J, Lidman C, Nowak P. Efficacy of routine fecal microbiota transplantation for treatment of recurrent Clostridium difficile infection: a retrospective cohort study. Int J Microbiol. 2019;2019:7395127.
Nivet C, Duhalde V, Beaurain M, Delobel P, Quelven I, Alric L. Fecal microbiota transplantation for refractory Clostridioides difficile infection is effective and well tolerated even in very old subjects: a real-life study. J Nutr Health Aging. 2022;26(3):290-296.
Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245-1251.
Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489-495.
Vlachogiannis NI, Baker KF, Georgiopoulos G, et al. Clinical frailty, and not features of acute infection, is associated with late mortality in COVID-19: a retrospective cohort study. J Cachexia Sarcopenia Muscle. 2022;13(3):1502-1513.
Martí-Pastor A, Moreno-Perez O, Lobato-Martínez E, et al. Association between Clinical Frailty Scale (CFS) and clinical presentation and outcomes in older inpatients with COVID-19. BMC Geriatr. 2023;23(1):1.
Miller MA, Louie T, Mullane K, et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis. 2013;13:148.
Aronchick CA. Bowel preparation scale. Gastrointest Endosc. 2004;60(6):1037-1038.
Ianiro G, Valerio L, Masucci L, et al. Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study. Clin Microbiol Infect. 2017;23(5):337.e1-337.e3.
Luo Y, Tixier EN, Grinspan AM. Fecal microbiota transplantation for Clostridioides difficile in high-risk older adults is associated with early recurrence. Dig Dis Sci. 2020;65(12):3647-3651.
Onder G, Cesari M, Maggio M, Palmer P. Defining a care pathway for patients with multimorbidity or frailty. Eur J Intern Med. 2017;38:1-2.
Church S, Rogers E, Rockwood K, Theou O. A scoping review of the Clinical Frailty Scale. BMC Geriatr. 2020;20(1):393.
Pilotto A, Custodero C, Maggi S, Polidori MC, Veronese N, Ferrucci L. A multidimensional approach to frailty in older people. Ageing Res Rev. 2020;60:101047.
Covino M, Salini S, Russo A, et al. Frailty assessment in the emergency department for patients ≥80 years undergoing urgent major surgical procedures. J Am Med Dir Assoc. 2022;23(4):581-588.
Oviedo-Briones M, Laso ÁR, Carnicero JA, et al. A comparison of frailty assessment instruments in different clinical and social care settings: the frailtools project. J Am Med Dir Assoc. 2021;22(3):607-607.e12.
Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2016;315(2):142-149.
Agrawal G. Fecal microbiota transplantation for Clostridioides difficile in high-risk older adults: treat early, treat often. Dig Dis Sci. 2020;65(12):3425-3427.